RaQualia, Interprotein in drug discovery deal

RaQualia Pharma Inc. (JASDAQ:4579) and Interprotein Corp. (Osaka, Japan) partnered to discover and develop protein-protein interaction inhibitors for undisclosed pain indications. The companies said RaQualia will identify candidate compounds, and Interprotein will use its Engine for New Drug Design (INTENDD) technology for in silico screening of candidates. RaQualia is eligible for worldwide, exclusive rights to any products resulting from the deal. Interprotein is eligible for an undisclosed upfront payment, a contingency payment and research milestones. The companies could not be reached for details. RaQualia was up Y70 (11%) to Y720 on Friday. ...